Amgen: Today’s Review Critical For Anemia Reimbursements (AMGN)
Amgen (NASDAQ:AMGN) has a huge day ahead of it. The biotech giant is presenting data today on the appropriateuse of Erythropoiesis Stimulating Agents in Chronic RenalFailure patients to a joint meeting of…